BR112017017211A2 - composto, composição, sal farmaceuticamente aceitável de um composto, combinação, formulação farmacêutica, métodos para matar uma micobactéria e/ou inibir a replicação de micobactérias que causam doença em um animal, para tratamento de uma infecção micobacteriana em um animal e para tratamento de uma doença resultante de uma infecção por micobactéria de um mamífero, e, uso de um composto. - Google Patents
composto, composição, sal farmaceuticamente aceitável de um composto, combinação, formulação farmacêutica, métodos para matar uma micobactéria e/ou inibir a replicação de micobactérias que causam doença em um animal, para tratamento de uma infecção micobacteriana em um animal e para tratamento de uma doença resultante de uma infecção por micobactéria de um mamífero, e, uso de um composto.Info
- Publication number
- BR112017017211A2 BR112017017211A2 BR112017017211-9A BR112017017211A BR112017017211A2 BR 112017017211 A2 BR112017017211 A2 BR 112017017211A2 BR 112017017211 A BR112017017211 A BR 112017017211A BR 112017017211 A2 BR112017017211 A2 BR 112017017211A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- animal
- treating
- mycobacterial infection
- mammal
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 206010062207 Mycobacterial infection Diseases 0.000 title abstract 3
- 208000027531 mycobacterial infectious disease Diseases 0.000 title abstract 3
- 241000124008 Mammalia Species 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 241001465754 Metazoa Species 0.000 title 2
- 201000010099 disease Diseases 0.000 title 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 2
- 241000186359 Mycobacterium Species 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000010076 replication Effects 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- GDMJXXLVTYSBBE-UHFFFAOYSA-N 1,2-benzoxaborole Chemical class C1=CC=C2OB=CC2=C1 GDMJXXLVTYSBBE-UHFFFAOYSA-N 0.000 abstract 1
- 239000003926 antimycobacterial agent Substances 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/04—Esters of boric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
benzoxaboróis substituídos cujas estruturas compreendem a fórmula (iii), em que r3 é selecionado a partir de -ch3, -ch2ch3, -ch2=ch2, -ch2ch2ch3, -ch(ch3)2, -ch2ch2=ch2 e ciclopropila, cada um de r1 e r2 são independentemente selecionados de h, -ch3, -ch2ch3, -ch2ch2ch3 e -ch(ch3)2; composições contendo tais compostos, a seu uso em terapia, incluindo seu uso como agentes anti-micobacterianos, por exemplo no tratamento de uma infecção por micobactéria em um mamífero, e métodos para a preparação de tais compostos.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15382054.3 | 2015-02-12 | ||
| EP15382054 | 2015-02-12 | ||
| EP15382055 | 2015-02-12 | ||
| EP15382056 | 2015-02-12 | ||
| EP15382056.8 | 2015-02-12 | ||
| EP15382055.0 | 2015-02-12 | ||
| PCT/IB2016/050775 WO2016128948A1 (en) | 2015-02-12 | 2016-02-12 | 4 -substituted benzoxaborole compounds and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112017017211A2 true BR112017017211A2 (pt) | 2018-04-03 |
| BR112017017211B1 BR112017017211B1 (pt) | 2023-04-25 |
Family
ID=55409879
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017017213-5A BR112017017213A2 (pt) | 2015-02-12 | 2016-02-12 | composto, composição, sal farmaceuticamente aceitável de um composto, método para matar uma micobactéria e/ou inibir a replicação de micobactérias que causam doença em um animal, e, uso de um composto. |
| BR112017017211-9A BR112017017211B1 (pt) | 2015-02-12 | 2016-02-12 | Composto benzoxaborol 4-substituído ou sal farmaceuticamente aceitável do mesmo, formulação farmacêutica, combinação, e, uso de um composto ou sal farmaceuticamente aceitável do mesmo, de uma formulação farmacêutica ou de uma combinação |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017017213-5A BR112017017213A2 (pt) | 2015-02-12 | 2016-02-12 | composto, composição, sal farmaceuticamente aceitável de um composto, método para matar uma micobactéria e/ou inibir a replicação de micobactérias que causam doença em um animal, e, uso de um composto. |
Country Status (35)
| Country | Link |
|---|---|
| US (3) | US20180037595A1 (pt) |
| EP (2) | EP3256479B1 (pt) |
| JP (2) | JP2018506540A (pt) |
| KR (2) | KR20170117156A (pt) |
| CN (2) | CN107548398A (pt) |
| AU (3) | AU2016217508A1 (pt) |
| BR (2) | BR112017017213A2 (pt) |
| CA (2) | CA2976030C (pt) |
| CL (2) | CL2017002059A1 (pt) |
| CO (2) | CO2017008809A2 (pt) |
| CR (2) | CR20170371A (pt) |
| CY (1) | CY1123687T1 (pt) |
| DK (1) | DK3256479T3 (pt) |
| DO (2) | DOP2017000188A (pt) |
| EA (2) | EA036516B1 (pt) |
| ES (1) | ES2821951T3 (pt) |
| HR (1) | HRP20201597T1 (pt) |
| HU (1) | HUE051113T2 (pt) |
| IL (2) | IL253864B (pt) |
| LT (1) | LT3256479T (pt) |
| MA (2) | MA41494B1 (pt) |
| MX (2) | MX2017010413A (pt) |
| MY (1) | MY194004A (pt) |
| NZ (1) | NZ734379A (pt) |
| PE (2) | PE20171348A1 (pt) |
| PH (2) | PH12017501427A1 (pt) |
| PL (1) | PL3256479T3 (pt) |
| PT (1) | PT3256479T (pt) |
| RS (1) | RS60885B1 (pt) |
| SG (2) | SG11201706510YA (pt) |
| SI (1) | SI3256479T1 (pt) |
| TW (2) | TWI730953B (pt) |
| UA (1) | UA120527C2 (pt) |
| WO (2) | WO2016128949A1 (pt) |
| ZA (1) | ZA201705456B (pt) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AP2016009046A0 (en) * | 2013-08-09 | 2016-02-29 | Anacor Pharmaceuticals Inc | Tricyclic benzoxaborole compounds and uses thereof |
| CA3060396A1 (en) * | 2017-05-08 | 2018-11-15 | Glaxosmithkline Intellectual Property Development Limited | Sanfetrinem or a salt or ester thereof for use in treating mycobacterial infection |
| BR112020010927A2 (pt) | 2017-11-30 | 2020-12-01 | Boragen, Inc. | compostos de benzoxaborol e formulações dos mesmos |
| JP2021534247A (ja) | 2018-08-18 | 2021-12-09 | ボラゲン，インコーポレーテッド | 置換ベンゾキサボロールの固体形態およびその組成物 |
| CN110441344B (zh) * | 2019-06-25 | 2020-09-29 | 北京大学 | 一种基于固体核磁共振技术检测rna结构的方法 |
| WO2023246841A1 (en) * | 2022-06-23 | 2023-12-28 | Shanghai Micurx Pharmaceutical Co., Ltd. | Methods and uses of boron compounds in the treatment of nontuberculous mycobacterium infections and pharmaceutical compositions for treatment of same |
| AU2023287063A1 (en) * | 2022-06-23 | 2024-05-30 | Shanghai Micurx Pharmaceutical Co., Ltd. | Prodrugs of boron compounds and their use in treating bacterial infections |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9411587D0 (en) * | 1994-06-09 | 1994-08-03 | Zeneca Ltd | Compound, composition and use |
| EP0947498B1 (en) | 1996-12-02 | 2004-09-15 | Chisso Corporation | Optically active nitro alcohol derivatives, optically active amino alcohol derivatives, and process for preparing the same |
| DE60313357T2 (de) | 2002-12-02 | 2008-01-03 | Solvias Ag | Verfahren zur katalytischen hydrierung von kohlenstoff-heteroatom-doppelbindungen |
| KR101337045B1 (ko) | 2005-02-16 | 2013-12-05 | 아나코르 파마슈티칼스 인코포레이티드 | 보론함유 소분자 |
| WO2006096131A1 (en) | 2005-03-08 | 2006-09-14 | Agency For Science, Technology And Research | Chiral bisoxazoline catalysts |
| EP1976536A4 (en) | 2005-12-30 | 2011-03-02 | Anacor Pharmaceuticals Inc | SMALL MOLECULES CONTAINING BORON |
| TWM325238U (en) * | 2006-12-29 | 2008-01-11 | Universal Scient Ind Co Ltd | Voltage regulator and voltage regulating system |
| KR100848491B1 (ko) | 2007-01-16 | 2008-07-28 | 영진약품공업주식회사 | 베타아미노기를 갖는 2-싸이아졸리딘 유도체, 이의약학적으로 허용 가능한 염 및 이의 제조 방법 |
| JO3396B1 (ar) | 2007-06-20 | 2019-10-20 | Anacor Pharmaceuticals Inc | جزيئات صغيرة تحتوي على البورون |
| CN102256494A (zh) | 2008-12-17 | 2011-11-23 | 阿纳科制药公司 | (s)-3-氨甲基-7-(3-羟基-丙氧基)-3h-苯并[c][1,2]氧杂硼杂环戊-1-醇的多晶型物 |
| US20110124597A1 (en) * | 2009-09-25 | 2011-05-26 | Anacor Pharmaceuticals, Inc. | Boron containing small molecules |
| CA2794684C (en) | 2010-04-07 | 2018-04-24 | Glaxosmithkline Llc | Process for preparing benzoxaboroles |
| PL3251678T3 (pl) | 2010-09-07 | 2022-01-10 | Anacor Pharmaceuticals, Inc. | Pochodne benzoksaborolu do leczenia zakażeń bakteryjnych |
| CA2858799A1 (en) | 2011-12-22 | 2013-06-27 | Micurx Pharmaceuticals, Inc. | Tricyclic boron compounds for antimicrobial therapy |
| CN102739587B (zh) | 2012-06-16 | 2014-05-21 | 天地融科技股份有限公司 | 音频数据传输方法 |
| KR101636431B1 (ko) | 2013-07-30 | 2016-07-05 | 동아에스티 주식회사 | 트리사이클릭 벤즈옥사보롤 화합물, 이의 제조방법 및 용도 |
| AP2016009046A0 (en) * | 2013-08-09 | 2016-02-29 | Anacor Pharmaceuticals Inc | Tricyclic benzoxaborole compounds and uses thereof |
-
2016
- 2016-02-11 MA MA41494A patent/MA41494B1/fr unknown
- 2016-02-11 MA MA041495A patent/MA41495A/fr unknown
- 2016-02-12 MX MX2017010413A patent/MX2017010413A/es unknown
- 2016-02-12 ES ES16706002T patent/ES2821951T3/es active Active
- 2016-02-12 BR BR112017017213-5A patent/BR112017017213A2/pt not_active Application Discontinuation
- 2016-02-12 CR CR20170371A patent/CR20170371A/es unknown
- 2016-02-12 JP JP2017542053A patent/JP2018506540A/ja active Pending
- 2016-02-12 AU AU2016217508A patent/AU2016217508A1/en not_active Abandoned
- 2016-02-12 CN CN201680021488.3A patent/CN107548398A/zh active Pending
- 2016-02-12 PT PT167060029T patent/PT3256479T/pt unknown
- 2016-02-12 PL PL16706002T patent/PL3256479T3/pl unknown
- 2016-02-12 SG SG11201706510YA patent/SG11201706510YA/en unknown
- 2016-02-12 UA UAA201708405A patent/UA120527C2/uk unknown
- 2016-02-12 MX MX2017010414A patent/MX2017010414A/es unknown
- 2016-02-12 MY MYPI2017702943A patent/MY194004A/en unknown
- 2016-02-12 EP EP16706002.9A patent/EP3256479B1/en active Active
- 2016-02-12 SI SI201630941T patent/SI3256479T1/sl unknown
- 2016-02-12 EA EA201791671A patent/EA036516B1/ru unknown
- 2016-02-12 WO PCT/IB2016/050776 patent/WO2016128949A1/en active Application Filing
- 2016-02-12 WO PCT/IB2016/050775 patent/WO2016128948A1/en active Application Filing
- 2016-02-12 AU AU2016217507A patent/AU2016217507B2/en active Active
- 2016-02-12 LT LTEP16706002.9T patent/LT3256479T/lt unknown
- 2016-02-12 KR KR1020177025535A patent/KR20170117156A/ko unknown
- 2016-02-12 CA CA2976030A patent/CA2976030C/en active Active
- 2016-02-12 US US15/550,658 patent/US20180037595A1/en not_active Abandoned
- 2016-02-12 PE PE2017001401A patent/PE20171348A1/es not_active Application Discontinuation
- 2016-02-12 NZ NZ734379A patent/NZ734379A/en unknown
- 2016-02-12 CA CA2976308A patent/CA2976308A1/en not_active Abandoned
- 2016-02-12 EA EA201791667A patent/EA201791667A1/ru unknown
- 2016-02-12 SG SG11201706511TA patent/SG11201706511TA/en unknown
- 2016-02-12 BR BR112017017211-9A patent/BR112017017211B1/pt active IP Right Grant
- 2016-02-12 CR CR20170372A patent/CR20170372A/es unknown
- 2016-02-12 RS RS20201204A patent/RS60885B1/sr unknown
- 2016-02-12 JP JP2017541999A patent/JP6771472B2/ja active Active
- 2016-02-12 US US15/550,693 patent/US10774096B2/en active Active
- 2016-02-12 HU HUE16706002A patent/HUE051113T2/hu unknown
- 2016-02-12 CN CN201680021538.8A patent/CN107531730B/zh active Active
- 2016-02-12 PE PE2017001400A patent/PE20171432A1/es not_active Application Discontinuation
- 2016-02-12 KR KR1020177025539A patent/KR20170117158A/ko not_active Application Discontinuation
- 2016-02-12 DK DK16706002.9T patent/DK3256479T3/da active
- 2016-02-12 EP EP16706003.7A patent/EP3256480A1/en not_active Withdrawn
- 2016-02-15 TW TW105104376A patent/TWI730953B/zh not_active IP Right Cessation
- 2016-02-15 TW TW105104422A patent/TW201702250A/zh unknown
-
2017
- 2017-08-07 IL IL253864A patent/IL253864B/en unknown
- 2017-08-07 IL IL253865A patent/IL253865A0/en unknown
- 2017-08-09 PH PH12017501427A patent/PH12017501427A1/en unknown
- 2017-08-09 PH PH12017501428A patent/PH12017501428A1/en unknown
- 2017-08-10 DO DO2017000188A patent/DOP2017000188A/es unknown
- 2017-08-10 DO DO2017000189A patent/DOP2017000189A/es unknown
- 2017-08-11 CL CL2017002059A patent/CL2017002059A1/es unknown
- 2017-08-11 ZA ZA201705456A patent/ZA201705456B/en unknown
- 2017-08-11 CL CL2017002060A patent/CL2017002060A1/es unknown
- 2017-08-29 CO CONC2017/0008809A patent/CO2017008809A2/es unknown
- 2017-08-29 CO CONC2017/0008816A patent/CO2017008816A2/es unknown
-
2020
- 2020-09-11 US US17/018,301 patent/US11214582B2/en active Active
- 2020-10-07 HR HRP20201597TT patent/HRP20201597T1/hr unknown
- 2020-10-14 AU AU2020256369A patent/AU2020256369A1/en not_active Abandoned
- 2020-10-15 CY CY20201100978T patent/CY1123687T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017017211A2 (pt) | composto, composição, sal farmaceuticamente aceitável de um composto, combinação, formulação farmacêutica, métodos para matar uma micobactéria e/ou inibir a replicação de micobactérias que causam doença em um animal, para tratamento de uma infecção micobacteriana em um animal e para tratamento de uma doença resultante de uma infecção por micobactéria de um mamífero, e, uso de um composto. | |
| BR112016002651A2 (pt) | composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, combinação, formulação farmacêutica, métodos para exterminar uma micobactéria e/ou inibir a replicação das micobactérias, e para tratar uma infecção e uma doença, e, uso de um composto | |
| BR112022012641A2 (pt) | Compostos tricíclicos substituídos | |
| CY1120248T1 (el) | Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου | |
| MA40111A1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
| BR112018007772A2 (pt) | compostos de imidazo[4,5-c]quinolin-2-ona e seu uso no tratamento do câncer | |
| BR112015029512A8 (pt) | derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas | |
| BR112021025964A2 (pt) | Formas de sal de ácido bempedoico e métodos para uso das mesmas | |
| AR101177A1 (es) | Inhibidores de la syk | |
| BR112017016487A2 (pt) | 7-benzil-4- (2-metilbenzil) -2,4,6,7,8,9-hexahidroimidazo [1,2-a] pirrido [3,4-e] pirimidin-5 (1h) -ona, análogos desta, e sais do mesmo e métodos para sua utilização na terapia | |
| BR112016028819A2 (pt) | composição farmacêutica, métodos para tratar uma doença ou condição em um ser humano e para inibir a atividade de um polipeptídeo de fosfatidilinositol 3-quinase e reações imunológicas excessivas ou destrutivas ou o crescimento ou a proliferação de células cancerosas, kit, composto, sal farmaceuticamente aceitável, isômero ou mistura dos mesmos, e, uso de um composto, sal farmaceuticamente aceitável ou mistura dos mesmos. | |
| BR112016028876A2 (pt) | composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos. | |
| BR112016028642A2 (pt) | composto, composição farmacêutica, método de tratamento de uma doença ou condição, método de inibição da atividade de um polipeptídeo de fosfatidilinositol 3-quinase, método de inibição de reações imunes ou crescimento excessivo ou destrutivo ou de proliferação de células cancerosas, kit, e, uso de um composto, de um sal, de um isômero ou de uma mistura farmaceuticamente aceitável do mesmo. | |
| BR112013006030A2 (pt) | composto e sais, solvatos, n-óxidos ou prodrogas farmaceuticamente aceitáveis, composição farmacêutica, uso do composto, kit, método de tratamento de uma doença, e, composição anti-helmíntica | |
| BR112022010377A2 (pt) | Novos tiromiméticos | |
| EA201992090A1 (ru) | ДЕЙТЕРИРОВАННЫЕ СОЕДИНЕНИЯ ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА | |
| EA201990765A1 (ru) | Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок | |
| BR112021025764A2 (pt) | Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo | |
| BR112017017275A2 (pt) | composto, composição farmacêutica, método para o tratamento e uso do composto | |
| BR112021020297A2 (pt) | Compostos de hexa-hidro-1h-pirazino[1,2-a]pirazina para o tratamento de doença autoimune | |
| PH12019500618A1 (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease | |
| CY1124301T1 (el) | Ενωσεις ινδαζολης για χρηση σε κακωσεις του τενοντα ή/και των συνδεσμων | |
| BR112017021583A2 (pt) | métodos para o tratamento de transtornos inflamatórios | |
| DOP2019000299A (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
| EA201891319A1 (ru) | Соединения алкилдигидрохинолинсульфонамида |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/02/2016, OBSERVADAS AS CONDICOES LEGAIS |